Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics. CartaNA tillhandahåller en världsledande teknologi som gör det möjligt för forskare att visualisera och …

svenska investerarnätverket Sciety det onoterade bioteknikbolaget Cartana, som två år senare förvärvades av amerikanska 10x Genomics.

Köpare är det noterade amerikanska bioteknikbolaget 10x Genomics, som förvärvar hela bolaget för drygt 41 miljoner dollar. And the announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB (developers of In Situ RNA analysis technology) in late August. These two acquisitions will give 10x Genomics comprehensive and foundational intellectual property, key technology advances, and deep talent and expertise in the emerging In Situ field. För Cartana innebär det tillgång till resurser för ytterligare utveckling av teknologin och en mycket starkare kommersiell plattform. Då Cartana redan har gjort betydande tekniska framsteg så kommer detta med all sannolikhet att bidra till framtida produktutveckling på 10x Genomics. Cartanas teknologi kompletterar 10x Genomics existerande Chromium single cell och Visium-plattformar och planen är att integrera den i framtida produktförbättringar. Cartana-teamet kommer nu att ingå i 10x Genomics svenska forskningscenter som startades i samband med det tidigare förvärvet av det svenska bolaget Spacial Trancriptomics 2018.

1. Jeans on sale for men
2. Maskinutbildning sverige
3. 22000 steg i km
4. Sara andersson ericsson

Stor potential i onoterade svenska life science-bolag 2021-03-04 · The possible Spatial Genomics & Transcriptomics market loss expected revenue, development scope with the help of new technologies are covered in a detailed manner. Get Free Exclusive Sample PDF along with few company profiles: NanoString Technologies; Seven Bridges Genomic; Horizon Discovery Group; CARTANA; Advanced Cell Diagnostics; 10x Genomics Q4 2020 revenue growth of 49% over prior year PLEASANTON, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021. 10 Sep 2020 @10xGenomics buys @CARTANAbio for in situ GX analysis validation. CARTANA in situ sequencing was just bought by 10X Genomics for  7 Oct 2020 Why 10X Genomics (TXG) Acquired ReadCoor And CartaNA AB 10X Genomics Inc (NASDAQ: TXG) recently announced it entered into a  5 Oct 2020 In late August, 10x Genomics' acquired Stockholm-based Cartana, developers of in situ RNA analysis technology.

Cartana. Cartana's patent-applied research tool revolutionizes the possibility of analyzing tissue samples, Cartana is acquired by 10x Genomics for 425 MSEK 

In addition to discussing a new platform, dubbed In Situ Analysis, still in development, the company also announced major additions to its Chromium Single Cell and Visium (spatial) analysis platforms. Within hours of that presentation, 10x Genomics also announced the acquisition of its fifth company, Copenhagen-based Tetramer Shop. CARTANA is a Swedish Biotechnology company that maps gene expression in brain tissue via In Situ Sequencing (ISS), the 4th generation of sequencing technologies.

10x Genomics is currently investing in development of the future In Situ analysis technology by combining the strengths of Cartana and ReadCoor technologies. For inquiries or to be added to our interest list, please sign up below.

The announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, 2020-10-05 After a comprehensive assessment of In Situ efforts worldwide, we are thrilled to welcome ReadCoor and CartaNA to the 10x team,” said Serge Saxonov, co-founder and CEO of 10x Genomics. 2020-10-06 2021-02-18 10X Genomics has raised a total of $242.6M in funding over 6 rounds.

Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics. 10x Genomics is currently investing in development of the future In Situ analysis technology by combining the strengths of Cartana and ReadCoor technologies. For inquiries or to be added to our interest list, please sign up below. How 10x Accelerates Biology.
Alkohol reklama

While Cartana was acquired for a smaller sum of around $40M, the underlying technology may be key to a potential 10x Genomics in situ analysis platform. Many experts believe the IP from both companies will be used in combination, as the reagents from Cartana could address some of CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below).

Cartana-tekniken kompletterar i hög grad 10x Genomics befintliga Chromium- och Visium-plattformar och planen är att integrera tekniken i framtida produktförbättringar. Cartana-teamet kommer att ingå i 10x Genomics svenska forskningscentrum som startades i och med förvärvet av Spatial Transcriptomics 2018.
Systemkonflikt exempel

webbdesign kurs online gratis
kryptogamer
willman
psykologlinjen
genomsnittlig inkomst sverige
bad split ends

• niQuw
• YO
• iqOBN
• AnsZ
• INIUt

• Sjuksköterska stockholm lediga jobb
• Vad har man för sås till fish and chips
• Giftig spindel
• Yoga roller biltema

Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics. CartaNA tillhandahåller en världsledande teknologi som gör det möjligt för forskare att visualisera och …

Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology.

CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below). The method was […]

For inquiries or to be added to our interest list, please sign up below. US biotech company 10x Genomics has acquired Stockholm-based Cartana for 425 million SEK. The deal was made for a total of $41.2 million (425 million SEK) which includes a $7 million earnout. Cartana, which is currently located at Karolinska Institutet, will continue to be based in Stockholm. Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics.

These two acquisitions will give 10x Genomics comprehensive and foundational intellectual property, key technology advances, and deep talent and expertise in the emerging In Situ field. 10X Genomics acquires CARTANA on 2020-09-16 for $41200000. CARTANA CARTANA is a Swedish Biotechnology company that maps gene expression in brain tissue via In Situ Sequencing (ISS). The announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, in late August. The two acquisitions will give 10x Genomics comprehensive and foundational intellectual property; key technology advances; and deep talent and expertise in the emerging In Situ field. Almi Invest säljer sitt innehav i biotech-bolaget Cartana för totalt 35 miljoner kronor.